Silence Therapeutics PLC(SLN) - 2023 Q4 - Annual Report

Exhibit 99.1 Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a) The 60-week study is ongoing and secondary endpoints, including change in Lp(a) from baseline to 48 weeks (end of treatment period), 60 weeks (end of study) and potential effects on other lipids/lipoproteins, will be evaluated. "We are excited about the emerging phase 2 data, which are very consistent with phase 1 results and support a competitive profile fo ...